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Objective: The aim of this study was to evaluate the association of serum magnesium levels
with proton pump inhibitors (PPIs) use and other factors.
Methods: Thiswas a cross-sectional study of 151 patients admittedwith acute diseases in the
Internal Medicine Division of the Hospital de Clinicas de Porto Alegre, after the exclusion
of conditions that are commonly associated with hypomagnesemia: diarrhea; vomiting;
chronic alcohol use; severely uncompensateddiabetesmellitus; and chronic use of laxatives,
diuretics or other drugs causing magnesium deﬁciency.
Results: All patients had normal serum magnesium levels. Serum albumin and creatinine
levels were positively associated with serum magnesium levels, after adjusting for con-
founders. There was no difference between mean serum magnesium levels of PPI users and
non-users, nor between men and women; there was also no correlation among age, serum
phosphorus, and potassium levels with serum magnesium levels. Limitations of this study
include the absence of an instrument for measuring adherence to PPI use and the sample
size.
Conclusion: The association of PPI use and hypomagnesemia is uncommon. Congenital
defects in the metabolism of magnesium may be responsible for hypomagnesemia in some
patients using this drug class.
© 2013 Elsevier Editora Ltda.
Magnésio sérico e uso de inibidores de bomba de prótons: estudo
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Objetivo: O objetivo desse estudo foi veriﬁcar a associac¸ão do nível sérico do magnésio com
o uso de inibidores de bomba de prótons (IBP) e outros fatores.
Métodos: Realizou-se estudo transversal com 151 pacientes admitidos com doenc¸as agudas
no servic¸o de medicina interna do Hospital de Clínicas de Porto Alegre. Foram excluídos
aqueles pacientes com condic¸ões usualmente relacionadas à hipomagnesemia: diarréia;
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vômitos; diabéticos agudamente descompensados; uso crônico de laxantes, álcool, diuréti-
cos ou outros fármacos relacionados.
Resultados: Todos os pacientes apresentaram níveis normais de magnésio. Albumina e cre-
atinina sérica se associaram positivamente com os níveis de magnésio sérico, após ajuste
para fatores confundidores. Não houve diferenc¸a no nível sérico de magnésio em usuários
ou não-usuários de IBP ou entre homens e mulheres. Não houve correlac¸ão com idade,
nível sérico de fósforo e potássio. As principais limitac¸ões desse estudo foram a ausência
de instrumento para medir a adesão aos IBPs e o tamanho da amostra.
Conclusão: A associac¸ão do uso de IBP e hipomagnesemia é rara. Defeitos congênitos no
metabolismo do magnésio devem ser responsáveis pelo surgimento de hipomagnesemia
em usuários de dessa classe de fármacos.
Introduction
The most potent drugs available to reduce gastric acid secre-
tion are the proton pump inhibitors (PPIs).1 PPIs selectively
and irreversibly inhibit the gastric H+/K+ ATPase. As this is
the ﬁnal step of acid secretion, this drug class has proved
to be more effective than other anti-secretory drugs.2 These
drugs are widely used, and they are generally safe and effec-
tive. However, there are recent reports associating PPI use and
magnesium deﬁciency.3–10
Magnesium is essential for the function of more than
300 cellular enzymes. Its deﬁciency can be accompanied by
hypocalcemia, hypokalemia, and serious neuromuscular and
cardiovascular problems.11
On March 2, 2011, the Food and Drug Administration (FDA)
issued a Drug Safety Communication informing the public
that prescription PPI drugs may cause low serum magnesium
levels if taken for prolonged periods of time.12 Nevertheless,
there is little knowledge about this association. Thus, the aim
of this study was to evaluate the prevalence of hypomagnes-
emia in patients with no other factors commonly associated
to low serum magnesium, admitted to the emergency room of
the Internal Medicine Division of the Hospital de Clinicas de
Porto Alegre (HCPA), a tertiary care facility in Southern Brazil.
Factors associated to serum magnesium levels were also stud-
ied.
Methods
Across-sectional studywas designed. The studywas approved
by the local ethics committee, andpatientswere includedafter
informed consent. Blood and urine samples were collected in
the morning, after a fast of at least four hours. Data such as
age, gender, use of PPI, and use of other medications were
obtained from medical charts. Patients with diarrhea or vomi-
ting, chronic alcohol use, and severe uncompensated diabetes
mellitus were excluded, as well as patients with chronic use
of laxatives, diuretics, and other drugs that could cause mag-
nesium deﬁciency, such as amphotericin B, aminoglycosides,
and cyclosporine.
Serum and urine were kept at -70 ◦C until biochemical
measurements in the same assay run. Serum and urinary
magnesium levels were measured by a method based on reac-
tion with blue xilidil. The magnesium ions react with blue
xilidil in an alkaline medium to form a water soluble pur-
ple/red complex. The increase in absorbance of the blue xilidil
at 505/694nm is proportional to the concentration of magne-
sium in the sample. The measurement was performed on the
device Advia® 1800, with normal range for serum magnesium:
1.3-2.7mg/dL.
Serum calcium, phosphorus, potassium, creatinine, albu-
min, and urine creatinine levels were measured according to
the HCPA routine.
Factors possibly associated with serum magnesium levels
were evaluated through Student’s t-test or the Mann-Whitney
test, and Pearson’s and Spearman’s correlation coefﬁcients,
when indicated. Results were considered as statistically sig-
niﬁcant when p < 0.05. Multiple linear regression was used to
isolate possible confounding variables. All analyses were per-
formed using the Statistical Package for Social Sciences (SPSS),
version 17.0.
Results
From September, 2010 to June, 2011 approximately
800 patients were admitted to the emergency room. Of
these, around 635 patients had exclusion criteria, 14 patients
refused to participate, and 151 patients were included in the
study. The baseline data are described in Table 1. Their ages
ranged from 17 to 94 years.
All patients had normal serummagnesium levels. Omepra-
zolewas the only PPI used in all patients treatedwith this drug
Table 1 – Baseline characteristics of patients using PPI
and non-users (n=151).
PPI (n=56) No PPI (n=95) p
Age (years) 62.0(52.3/72.0) 54.0(41/66) 0.11
Gender (n M/n F) 29/27 48/47 0.88
Serum magnesium (mg/dL) 1.97±0.20 2.00±0.25 0.33
Serum potassium (mEq/L) 4.51±0.47 4.39±0.48* 0.34
Serum calcium (mg/dL) 8.53± 0.74 8.54±0.59 0.27
Serum phosphorus (mg/dL) 3.30(2.53/3.68) 3.39(2.53/3.68) 0.12
Serum albumin (g/dL) 3.70±0.52 3.80±0.43 0.21
Serum creatinine (mg/dL) 0.88±0.35 0.86±0.49 0.42
M, male; F, female.
Data are shown as mean ± standard deviation or median (P25/P75).
∗ n=92.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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Fig. 1 – Relationship among serum magnesium, albumin, creatinine (mg/dL) and calcium levels. Pearson coefﬁcients are
shown.
class, andwas administered as a single dose 30minutes before
breakfast. 42 patients received 20mg and 14 received 40mg.
The reasons for PPI use included chronic gastritis with H.
pylori positive culture, dyspeptic symptoms, gastroesophageal
reﬂux disease, peptic duodenal ulcer, dyspepsia, gastritis, epi-
gastric pain, and esophageal hiatus hernia.
There was no difference (p=0.59) between the mean serum
magnesium levels of men (1.98 ± 0.27) and women (2.00 ±
0.19). There was no correlation between age and serum phos-
phorus or potassium levels with serum magnesium levels.
Serum albumin, creatinine, and calcium levels were positively
correlated with serum magnesium levels, as shown in Fig. 1.
After multiple linear regression, only serum albumin and
creatinine levels were independently associated with serum
magnesium levels (Table 2).
Discussion
In this study, no patient had hypomagnesemia, although 56
were using PPIs. The prevalence of hypomagnesemia was
lower than previously described in hospitalized patients,
ranging from 12% to 50%.13 This may be due to the
exclusion criteria of this study, which withdrew patients
with conditions or using drugs commonly associated to
hypomagnesemia, such as chronic diarrhea, vomiting, use
of diuretics, gentamicin, cisplatin, ciclosporin, and oth-
ers.
Data from this study suggest that the association between
PPI use and hypomagnesemia is uncommon. It is possible that
hypomagnesemia occurs in patients with genetic susceptibil-
ity, which may become clinically evident with PPI use. Several
inherited diseases were described as causing low serum mag-
nesium. Hypomagnesemia with secondary hypocalcemia is
Table 2 – Multiple linear regression analyses of factors
affecting variation of serum magnesium (n =151).
Variable B Beta p
Albumin 0.157 0.319 0.001
Creatinine 0.151 0.297 0.000
Calcium 0.029 0.083 0.439
Dependent variable, serum magnesium.
B, coefﬁcient; Beta, intercept.
caused by a defect in TRPM6 channel, present in the intestine
and renal tubules. The loss of function of TRPM6 leads to a
reduction in intestinal absorption of magnesium, also accom-
panied by decreased renal reabsorption of this cation.14,15
There are other hereditary causes of hypomagnesemia that
lead to renal losses, such as familial hypomagnesemia with
hypercalciuria and nephrocalcinosis, where a mutation in the
gene encoding claudin-16, a tight junction protein present
in the kidney responsible for the paracellular transport of
magnesium, decreases magnesium reabsorption. Gitelman’s
syndrome also affects renal transport, and is characterized by
hypomagnesemia and hipokalemia. Bartter’s syndrome may
have mutations of various proteins, and all these mutations
affect the transport of magnesium through the thick ascend-
ing loop of Henle.16
The mechanism of hypomagnesemia associated with PPI
use is unknown; however, there is a decrease in the intesti-
nal absorption of magnesium and the role of the kidney it is
not well established.9 As an increase in urinary excretion of
magnesium before correction of hypomagnesemia has been
observed in one patient, increased urinary loss cannot be
excluded.3 Although two patients described by Cundy et al.
presented increased urinary magnesium excretion only when
serummagnesium levelswere normal, after intravenousmag-
nesium infusion, it could not be excluded that other drugs
affecting renal magnesium handling could have contributed
to their results.9
Serum albumin and magnesium levels were positively cor-
related, as expected, since 30%ofmagnesiumcirculates bound
to this protein.11 For other ions such as calcium, the calcu-
lation of total serum concentration is performed considering
the albumin levels,17 but this correction is not usually rec-
ommended for magnesium. The positive correlation between
albumin and magnesium suggests that this correction should
also bemade for this ion in order to obtainmore reliable serum
values.
There was also a positive correlation between serum creat-
inine and magnesium levels. Serum magnesium increases in
the presence of kidney damage, reﬂected by increased blood
creatinine and decreased glomerular ﬁltration rate. This is due
to loss of the ability of the kidneys to properly excrete mag-
nesium. This correlation was expected, since it is also true for
other electrolytes.
Limitations of this study include the lack of an instru-
ment to measure adherence to the use of PPI, and the sample
rev assoc med bras . 2013;59(3):276–279 279
size. No patient had low levels of magnesium, so a larger
sample is needed to evaluate the prevalence of this adverse
effect.
Conclusion
PPI use did not affect mean serum magnesium levels in this
study. The association between PPI use and hypomagnesemia
is uncommon.
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